AlphaStocks
5.5
Consider Buy

Doximity, Inc. (DOCS)

As of Sep 20, 2026, Doximity, Inc. (DOCS) scores 5.5/10 on AlphaStocks' five-model composite, #79 of 168 Health Care stocks. At $26, DOCS trades 6% below its model fair value of $28.

Health Care / Health Care Technology

S&P MidCap 400

$26.11

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#79out of 168 in Health Care

Is Doximity, Inc. a Good Investment in 2026?

Doximity, Inc. (DOCS) scores 5.5 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Lynch model rates Doximity, Inc. as Strong (PEG 0.9 · Fast Grower). However, the Graham model rates it Caution — Significantly above fair value. Doximity, Inc. currently trades 6% below its estimated fair value of $28. Doximity, Inc. ranks #79 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E26.5ROE19.8Market Cap5B

Estimated Fair Value

$27.876% below

Trading slightly below estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Strong

PEG 0.9 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Doximity, Inc. (DOCS) a good investment?
As of Sep 20, 2026, Doximity, Inc. (DOCS) scores 5.5/10 on AlphaStocks' five-model composite, #79 of 168 Health Care stocks. At $26, DOCS trades 6% below its model fair value of $28. That is a middle-of-the-pack score with no strong signal either way.
What is Doximity, Inc.'s Piotroski F-Score?
Doximity, Inc.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is DOCS overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $28, DOCS appears undervalued. The stock currently trades 6% below its estimated fair value. Trading slightly below estimated fair value.
How does DOCS compare to other Health Care stocks?
Doximity, Inc. ranks #79 out of 168 stocks in the Health Care sector, placing it in the top 47% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about DOCS?
AlphaStocks evaluates DOCS using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Strong. These models are combined into a single composite score of 5.5/10.

Similar Stocks

SOLVVEEVCERT

Compare DOCS with

DOCS vs SOLVDOCS vs VEEVCERT vs DOCS

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer